GlassScriptPhysician profile
Heath H Hodapp
NPI 1447221270
$2,751.91
in general payments reported to CMS, 2019-2025
29 companies · $305 in 2025
The $305 reported for 2025 was more than what 85% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $240 · 2021: $954 · 2022: $342 · 2023: $207 · 2024: $391 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $577.40 | 2019-2025 | Bexsero, Pediarix, Penmenvy |
| Medline Industries LP | $360.65 | 2021 | |
| Supernus Pharmaceuticals, INC. | $305.78 | 2021-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $246.49 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $174.55 | 2021-2024 | |
| Sanofi Pasteur INC. | $168.44 | 2019-2025 | |
| Kaleo, INC. | $124.28 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $79.33 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.06 | 2020-2021 | |
| Cranial Technologies, INC | $71.37 | 2021-2025 | Doc Band |
| Corium, LLC | $63.65 | 2024 | Azstarys |
| Neos Therapeutics, LP | $60.23 | 2019-2020 | |
| Seqirus USA INC | $57.71 | 2022-2025 | Flucelvax |
| Kyowa Kirin, INC. | $47.72 | 2024 | Crysvita |
| Vertical Pharmaceuticals, LLC | $42.94 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $41.72 | 2019 | |
| Verrica Pharmaceuticals INC. | $35.05 | 2025 | Ycanth |
| Boston Scientific Corporation | $24.92 | 2019 | |
| Acadia Pharmaceuticals INC | $22.35 | 2023 | Daybue |
| Alexion Pharmaceuticals, INC. | $21.68 | 2024 | Koselugo |
| Biomarin Pharmaceutical INC. | $20.74 | 2024 | Voxzogo 1.2mg |
| Tris Pharma INC | $19.87 | 2019 | |
| Alk-Abello, INC | $18.85 | 2025 | Neffy |
| Shire North American Group INC | $18.22 | 2019 | |
| Avion Pharmaceuticals | $16.47 | 2023 | Methylphenidate Hydrochloride |
| Sobi, INC | $14.94 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.74 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.54 | 2021 | |
| Phadia US INC. | $13.22 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heath Hodapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.